Navigation Links
BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
Date:4/14/2009

WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S. with sites in the United Kingdom, Germany and Australia due to open later in the year. Further details on this study can be found at www.oncovexgmcsf.com and at www.clinicaltrials.gov.

Dr Robert Coffin, Founder and Chief Technology Officer of BioVex Inc said:

"The treatment options for patients with recurrent or metastatic melanoma are currently very limited, with no therapy being approved or recognized to be effective in the second line setting and beyond. Currently, there are also very few late stage or pivotal clinical studies available for patients who have failed first line therapy. The initiation of this study, following the highly encouraging data generated in Phase 2, is therefore a significant milestone on the path towards meeting this major unmet need, and towards the approval of OncoVEX (GM-CSF) in this first indication."

OPTiM Phase 3 Trial Design

The OPTiM trial is a multi-national, open label, randomized Phase 3 study designed to assess the efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to subcutaneously administered GM-CSF in patients with unresectable stage III (b-c) and Stage IV (M1a-c) disease. Patients will have received at least one prior therapy for active disease which includes any type of therapy including investigational drugs. A total of 360 patients will be enrolled (240 to
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Raises $40 Million in First Close of Series F Financing
2. BioVex to Present at the UBS Global Life Sciences Conference
3. BioVex Closes Second Round of Series E Financing
4. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
5. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Colo. , Aug. 26, 2014   Loveland ... global provider of high-performance crop input products and ... announced that the company has acquired a controlling ... -area agricultural biotechnology company delivering biochemical-based products for ... of Loveland Products, fastest growing plant nutrition brands, ...
(Date:8/26/2014)... 2014 Albany Molecular Research Inc. (NASDAQ: ... Marth , President and Chief Executive Officer at AMRI, ... on Monday, September 8, 2014 at 8:45 a.m. ET. ... presentation can be accessed at AMRI,s Investor Relations web ... will be archived for 90 days following the live ...
(Date:8/26/2014)... MA (PRWEB) August 26, 2014 ... solutions, today announced the release of Transform for ... for Electronic Data Capture (EDC) product line. It ... XClinical, and allows integration with MARVIN, the EDC ... as reducing study setup time, by allowing instantaneous ...
(Date:8/26/2014)... Spartan Bioscience today announced the ... Business Development. Mr. Shah is responsible for expanding ... in the United States and international markets. ... and strategic initiatives for the company’s rapid sample-to-result ... Shah was the Global Marketing Product Manager for ...
Breaking Biology Technology:Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 2Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 3Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 4Introducing Transform for MARVIN: Providing Further Flexibility for CROs and Sponsors in Partnership with XClinical 2Spartan Bioscience Names Charudutt Shah as Director of Business Development 2
... Behring, a world leader in the development of plasma-derived and ... CSL Behring – Prof. Heimburger Award 2011 . The ... this year,s theme to " Be Inspired, Get Involved in ... – Prof. Heimburger Award has been inspiring young medical ...
... SAN DIEGO, April 14, 2011 Promising new devices ... or heart failure, and related research, will be revealed ... Lung Transplantation (ISHLT) 31st Annual Meeting and Scientific Sessions. ... Neonates (PumpKIN) Program will be presented during the Meeting ...
... WORTH, Texas, April 14, 2011 The Wound Institute ... on dynamic reciprocity at the combined meeting of the ... Healing Society (WHS) being held in Dallas at the ... 2011. Presenting faculty are Dr. Ira M. Herman, tenured ...
Cached Biology Technology:CSL Behring Marks World Hemophilia Day by Announcing the Winners of the 'CSL Behring - Prof. Heimburger Award 2011' 2CSL Behring Marks World Hemophilia Day by Announcing the Winners of the 'CSL Behring - Prof. Heimburger Award 2011' 3CSL Behring Marks World Hemophilia Day by Announcing the Winners of the 'CSL Behring - Prof. Heimburger Award 2011' 4Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 2Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting 3The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 2The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 3The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting 4
(Date:8/25/2014)... battery-powered DNA diagnostic device invented at New Zealand,s ... commonly used field tool for rapidly detecting suspected ... the level of infection. , The breakthrough device, ... Queenstown Molecular Biology main meeting. It takes advantage ... target DNA sequences in real-time, without the need ...
(Date:8/25/2014)... of proteins that promotes virus entry into cells also ... and other viruses, University of Missouri researchers have found. ... insights into our understanding of not only HIV infection, ... Shan-Lu Liu, M.D., Ph.D., associate professor in the MU ... , The study was recently published in the ...
(Date:8/25/2014)... gentle and efficient cell separation from a device the ... to tilt-angle standing surface acoustic waves, according to a ... to do cell separation before analysis," said Tony Jun ... the separation process affects the integrity of the cells, ... work well.", Tilted-angle standing surface acoustic waves can separate ...
Breaking Biology News(10 mins):Revolutionary handheld DNA diagnostic unit allows lab-quality analysis in the field 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3Tilted acoustic tweezers separate cells gently 2
... 25, 2013   GenoVive , an innovator in personalized ... emerging "globesity" epidemic through its development of a state ... individual,s unique metabolism.  "Weight Loss Designed by Science" has ... an all natural meal and exercise program to assist ...
... After helping the US develop the atomic bomb, Niels ... was freely accessible. His thoughts remain highly relevant in ... of drones and space weapons in warfare raise questions ... consequences of technology. As part of the celebrations ...
... announced the release of a comprehensive, quality-controlled dataset that ... data on the massive Deepwater Horizon Oil Spill. The dataset, ... of dispersants, wraps up a three year process that began ... in the Gulf of Mexico during and after the oil ...
Cached Biology News:"GenoVive is changing the face of personalized health by continuing research efforts with Harvard." 2International Niels Bohr Conference: An open world 2NOAA launches website holding millions of chemical analyses from Deepwater Horizon oil spill 2
...
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
Biology Products: